JYONG BIOTECH LTD (MENS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:MENS • KYG831161065

2.36 USD
-0.2 (-7.81%)
At close: Jan 30, 2026
2.36 USD
0 (0%)
After Hours: 1/30/2026, 8:04:24 PM
Fundamental Rating

0

MENS gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. MENS has a bad profitability rating. Also its financial health evaluation is rather negative. MENS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • MENS had negative earnings in the past year.
  • In the past year MENS has reported a negative cash flow from operations.
MENS Yearly Net Income VS EBIT VS OCF VS FCFMENS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -2M -4M -6M

1.2 Ratios

  • The Return On Assets of MENS (-68.25%) is worse than 61.90% of its industry peers.
Industry RankSector Rank
ROA -68.25%
ROE N/A
ROIC N/A
ROA(3y)-58.86%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MENS Yearly ROA, ROE, ROICMENS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 20 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MENS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MENS Yearly Profit, Operating, Gross MarginsMENS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

  • The number of shares outstanding for MENS remains at a similar level compared to 1 year ago.
  • MENS has a worse debt/assets ratio than last year.
MENS Yearly Shares OutstandingMENS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 20M 40M 60M
MENS Yearly Total Debt VS Total AssetsMENS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • Based on the Altman-Z score of -8.36, we must say that MENS is in the distress zone and has some risk of bankruptcy.
  • MENS's Altman-Z score of -8.36 is on the low side compared to the rest of the industry. MENS is outperformed by 68.38% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.36
ROIC/WACCN/A
WACCN/A
MENS Yearly LT Debt VS Equity VS FCFMENS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 10M -10M -20M -30M

2.3 Liquidity

  • A Current Ratio of 0.02 indicates that MENS may have some problems paying its short term obligations.
  • MENS has a worse Current ratio (0.02) than 95.62% of its industry peers.
  • MENS has a Quick Ratio of 0.02. This is a bad value and indicates that MENS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • MENS has a Quick ratio of 0.02. This is amonst the worse of the industry: MENS underperforms 95.62% of its industry peers.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
MENS Yearly Current Assets VS Current LiabilitesMENS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M

More info and screens

0

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 24.04% over the past year.
EPS 1Y (TTM)24.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • MENS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MENS Price Earnings VS Forward Price EarningsMENS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MENS Per share dataMENS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • MENS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

JYONG BIOTECH LTD / MENS FAQ

What is the fundamental rating for MENS stock?

ChartMill assigns a fundamental rating of 0 / 10 to MENS.


What is the valuation status for MENS stock?

ChartMill assigns a valuation rating of 0 / 10 to JYONG BIOTECH LTD (MENS). This can be considered as Overvalued.


What is the profitability of MENS stock?

JYONG BIOTECH LTD (MENS) has a profitability rating of 0 / 10.


How financially healthy is JYONG BIOTECH LTD?

The financial health rating of JYONG BIOTECH LTD (MENS) is 0 / 10.